fbpx
SPEAKER

DAY 1

Speaker

https://aisummit.co.kr/wp-content/uploads/2020/10/Konrad-Dobschuetz.jpg

Konrad Dobschuetz  Novartis | Head of Digital Innovation

Konrad Dobschuetz works in Novartis as Head of Customer Solutions, Digital & Health Innovation and BIOME UK. He has a track record of successfully on-boarding start-ups as well as creating strategic frameworks for innovation enablement. Konrad has looked after scale digital transformation projects for international companies like Pfizer, MasterCard, Canon and GE Healthcare across Europe and Developed Markets including South Korea. He has long-term experience in e-commerce, omni-channel marketing, commercialisation of assets and strategy development. For the past few years Konrad has also been working on AI and Blockchain innovation projects, applying Six Sigma principles. 

In the community, Konrad is known as a technology philosopher, asking difficult questions and always trying new things.  As a speaker internally and externally, he likes to help others in up-skilling all things digital weird and wonderful, as he is still trying to solve the mysteries of the universe made of a piece of string.

The Novartis BIOME: A Catalyst for Innovation in Healthcare using AI, Data and Technology

The Novartis BIOME is a place for change. We believe in uniting the best of science and technology to create better healthcare solutions and seamless experiences for patients and caregivers, at scale.

Not to be confused with an accelerator or incubator, we allow teams to co-develop digital solutions alongside specific therapeutic offerings, research activities, and business processes within Novartis. Konrad will talk about a UK use-case and open the floor for start-ups to collaborate with Novartis in the UK and globally.

At the same time, we provide external innovators with the resources and opportunities they need to validate their solutions through access to regulatory, medical or legal expertise, as well as data sandboxes linked to over 2 million patient years of clinical trial data, and in some cases, investment and financing.